Thomas Bieber

34PUBLICATIONS
115CO-AUTHORS
Professional writing and journalism practiceCancer therapy (excl. chemotherapy and radiation therapy)BiomechanicsAllergyCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Aug 04, 2026
Response to letter to the editor: sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

|Jul 31, 2026
Reassessing the OX40/OX40L axis in atopic dermatitis after the termination of Rocatinlimab's clinical development program.

|May 21, 2026
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

|May 19, 2026
From Sprinters to Marathoners: Rethinking Therapeutic Speed and Disease Modification in Atopic Dermatitis.

|Oct 02, 2025
Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.

Gilles Tiraboschi, Kim Papp, Thomas Bieber

|Sep 23, 2025
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Eric L Simpson, Jonathan I Silverberg, Bob Geng

Pageof 6

Frequent Collaborators

7 joint publications

Laura Maintz

5 joint publications

Stephan Weidinger

4 joint publications

Emma Guttman-Yassky

4 joint publications

Claudia Traidl-Hoffmann